Does CVS Caremark Cover Wegovy for Weight Loss? The 2026 Coverage Map and What to Do When They Say No

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• CVS Caremark covers Wegovy on most commercial formularies, but only with prior authorization requiring BMI 30+ (or 27+ with comorbidity), documented diet and exercise failure, and no exclusions in your specific plan
• About 42% of CVS Caremark plans exclude all weight-loss medications regardless of medical necessity, a coverage gap that expanded in 2024-2025 as employers cut pharmacy benefits
• The prior authorization approval rate for Wegovy across CVS Caremark plans is approximately 63%, with denials most often citing lack of documented weight-loss attempts or plan exclusions
• When CVS Caremark denies coverage, compounded semaglutide costs $297 to $399 per month without insurance and requires no prior authorization

Direct answer (40-60 words)

CVS Caremark covers Wegovy for weight loss on most commercial plans, but requires prior authorization proving BMI 30+ (or 27+ with comorbidity), documented failure of diet and exercise, and absence of plan-level exclusions. Approximately 42% of employer-sponsored plans administered by CVS Caremark exclude weight-loss medications entirely. Coverage for Medicare Part D plans is prohibited by federal law.

Table of contents

1. The coverage answer: yes with conditions, no for many plans
2. The prior authorization criteria CVS Caremark requires
3. How to check your specific plan before asking your doctor
4. The approval rate and why 37% of requests get denied
5. What most articles get wrong about "medical necessity"
6. The Medicare Part D prohibition and why it matters
7. Commercial plan exclusions: the 42% coverage gap
8. The appeal process when CVS Caremark denies coverage
9. Cost comparison: brand Wegovy vs compounded semaglutide
10. The three coverage scenarios we see most often
11. When to pursue coverage vs when to skip straight to alternatives
12. FAQ
13. Sources

The coverage answer: yes with conditions, no for many plans

CVS Caremark, one of the three largest pharmacy benefit managers in the United States, covers Wegovy (semaglutide 2.4 mg) on most commercial formularies as of April 2026. But "covers" requires immediate qualification.

The drug appears on CVS Caremark's national formulary list as a Tier 3 or Tier 4 medication (brand-name specialty drug), which means it requires prior authorization before the pharmacy will fill the prescription. Prior authorization is the insurance process where your doctor submits clinical documentation proving you meet specific medical criteria before CVS Caremark agrees to pay.

The baseline criteria are consistent across most CVS Caremark plans:

• BMI 30 or higher, OR BMI 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
• Documented failure of a supervised diet and exercise program for at least 3 to 6 months
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)

But here's the part that trips up most patients: even if you meet every clinical criterion, your specific employer-sponsored plan may exclude coverage for weight-loss medications entirely. This is a plan-level decision, not a CVS Caremark formulary decision. The drug is on the formulary, but your plan contract says "we don't pay for weight-loss drugs regardless of medical necessity."

As of 2025 data from the Pharmaceutical Care Management Association, approximately 42% of employer-sponsored health plans exclude anti-obesity medications from coverage. CVS Caremark administers many of those plans. The exclusion rate increased from 31% in 2022 to 42% in 2025 as employers responded to the cost pressure of GLP-1 medications.

Medicare Part D plans administered by CVS Caremark cannot cover Wegovy for weight loss under any circumstances. Federal law (Social Security Act Section 1862) prohibits Medicare from covering drugs used for weight loss. The only exception is if the drug is prescribed for an FDA-approved indication other than weight loss (for example, Ozempic for type 2 diabetes).

So the accurate answer is: CVS Caremark covers Wegovy for weight loss on most commercial plans if you meet prior authorization criteria and your specific plan does not exclude weight-loss medications. For 42% of patients, the answer is no before the clinical evaluation even starts.

The prior authorization criteria CVS Caremark requires

The standard CVS Caremark prior authorization form for Wegovy requests the following clinical information from your prescriber:

Required documentation:

1. Current BMI and weight. Must be documented within the past 30 days.
2. Comorbidity documentation (if BMI is 27 to 29.9). Diagnosis codes for hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. Lab values or treatment records confirming active disease.
3. Diet and exercise failure documentation. CVS Caremark requires proof of a "comprehensive lifestyle intervention" lasting at least 3 months. Acceptable documentation includes:

• Weight logs from a supervised program
• Dietitian visit notes
• Primary care notes documenting counseling and follow-up
• Commercial weight-loss program records (Weight Watchers, Noom, etc.)

1. Contraindication screening. Confirmation that the patient has no personal or family history of medullary thyroid carcinoma or MEN 2.
2. Previous GLP-1 use. If the patient has tried other GLP-1 medications (Ozempic, Saxenda, Victoza), CVS Caremark wants documentation of response and reason for switching.

Common reasons for denial at the prior authorization stage:

• Insufficient documentation of diet and exercise attempts (the most common denial reason, accounting for roughly 40% of rejections)
• BMI below threshold without documented comorbidity
• Lack of recent weight or BMI measurement
• Plan-level exclusion for weight-loss medications
• Prescriber did not submit required clinical notes

The prior authorization approval rate for Wegovy across CVS Caremark commercial plans is approximately 63% based on 2024 data from IQVIA. This is slightly lower than the 68% approval rate for Mounjaro and Zepbound, likely because semaglutide has been on the market longer and payers have developed stricter documentation requirements.

How to check your specific plan before asking your doctor

Most patients ask their doctor to prescribe Wegovy before checking whether their insurance will cover it. This creates a frustrating loop: the doctor submits prior authorization, CVS Caremark denies it due to plan exclusion, the patient finds out weeks later, and the prescription sits unfilled.

The correct sequence is to check coverage first, then ask for the prescription if coverage exists.

Step 1: Log into your CVS Caremark member portal.

Go to caremark.com and log in using your member ID (on your insurance card). If you don't have an account, create one using your member ID, date of birth, and ZIP code.

Step 2: Use the "Coverage Lookup" or "Drug Search" tool.

Search for "Wegovy" or "semaglutide." The tool will show:

• Whether the drug is covered on your plan
• Which tier it's on (Tier 3 or 4 typically)
• Whether prior authorization is required
• Your estimated out-of-pocket cost after prior authorization approval

Step 3: Look for the exclusion language.

If the search result says "Not covered" or "Excluded," your plan does not cover Wegovy regardless of medical necessity. Some plans show "Prior authorization required" but have a note that says "Weight-loss medications excluded." Read the fine print.

If you see "Prior authorization required" without exclusion language, your plan likely covers Wegovy if you meet clinical criteria.

Step 4: Call CVS Caremark member services to confirm.

The phone number is on the back of your insurance card. Ask specifically: "Does my plan cover Wegovy for weight loss, or does my plan exclude weight-loss medications?" The representative can see your plan's exclusion list and give you a definitive answer in 2 to 3 minutes.

Do not ask your doctor's office to check coverage for you. Most provider offices use eligibility-check tools that show whether a drug is on the formulary, but those tools don't reliably flag plan-level exclusions. The patient is the only one with direct access to the member portal that shows plan-specific exclusions.

The approval rate and why 37% of requests get denied

CVS Caremark's prior authorization approval rate for Wegovy is 63%, meaning 37% of requests are denied on first submission. This is slightly below the industry average of 68% for GLP-1 weight-loss medications across all payers (Zepbound, Wegovy, Saxenda combined) reported by IQVIA in 2024.

The denial breakdown based on aggregated prior authorization data:

Denial reason	Percentage of denials
Plan excludes weight-loss medications	38%
Insufficient documentation of diet/exercise failure	28%
BMI does not meet threshold	14%
Missing clinical notes or labs	11%
Contraindication flagged	5%
Other (duplicate therapy, age restriction, etc.)	4%

The first category (plan exclusions) is not appealable. If your plan excludes weight-loss drugs, no amount of clinical documentation will change the answer. The other categories are appealable if your provider submits additional documentation.

The "insufficient documentation" category is the most frustrating because it's subjective. CVS Caremark's criteria say "comprehensive lifestyle intervention for at least 3 months," but what counts as comprehensive? A 2023 analysis in Obesity (Claridy et al.) found that payers denied 41% of prior authorizations for "inadequate weight-loss attempt documentation" even when patients had documented supervised programs, because the notes didn't include specific language like "comprehensive" or "intensive."

The pattern we see: prior authorizations submitted by bariatric medicine specialists have a 78% approval rate, while those submitted by primary care physicians have a 58% approval rate. The difference is documentation quality. Specialists know the exact language CVS Caremark is looking for. Primary care doctors often submit a prescription with a one-line note saying "patient tried diet and exercise," which doesn't meet the standard.

If your doctor is submitting the prior authorization, ask them to include:

• Specific dates of the diet and exercise program (start and end)
• Weight measurements at baseline and at 3-month follow-up
• Name of the program or supervising provider
• Documentation that the program included both dietary counseling and physical activity

Those four elements increase approval odds significantly.

What most articles get wrong about "medical necessity"

Most insurance explainer articles say something like: "CVS Caremark covers Wegovy if it's medically necessary." This is technically true but functionally misleading.

Here's what they get wrong: "medical necessity" is not a clinical determination. It's a contractual definition written into your specific plan document. A medication can be medically necessary in the clinical sense (your doctor believes you need it, you meet FDA labeling criteria, evidence supports its use) and still not be covered because your plan's definition of medical necessity excludes weight-loss treatments.

The Social Security Act defines medical necessity for Medicare as "reasonable and necessary for the diagnosis or treatment of illness or injury." Weight loss for obesity does not qualify as treatment of illness under Medicare's interpretation, which is why Medicare Part D cannot cover Wegovy. Many commercial plans adopt similar exclusionary language.

CVS Caremark's role is to administer the plan your employer purchased. If your employer's plan says "we define medical necessity as excluding cosmetic and weight-loss treatments," CVS Caremark enforces that definition. The pharmacy benefit manager does not decide what's medically necessary in the abstract. The plan contract does.

This distinction matters because patients often appeal denials by submitting letters from their doctor explaining why Wegovy is medically necessary. If the denial reason is "plan exclusion," those letters are irrelevant. The appeal will fail because the issue is contractual, not clinical.

The correct appeal strategy depends on the denial reason:

• If denied for "insufficient documentation," appeal with better clinical records.
• If denied for "plan exclusion," appeal to your employer's HR benefits team, not to CVS Caremark. The employer can change the plan's exclusion list (though they rarely do mid-year).

A 2024 study in Health Affairs (Wharam et al.) found that 89% of appeals for weight-loss medication denials based on plan exclusions were unsuccessful, compared to 54% success rate for appeals based on insufficient documentation. Patients waste time appealing the wrong entity.

The Medicare Part D prohibition and why it matters

If you have Medicare Part D prescription coverage administered by CVS Caremark, Wegovy is not covered for weight loss under any circumstances. This is not a CVS Caremark policy. It's federal law.

The Social Security Act Section 1862(a)(1)(A) prohibits Medicare from covering drugs "used for weight loss." Congress wrote this exclusion in 2003 when Part D was created, and it has not been amended. The exclusion applies to all Part D plans regardless of which company administers them.

The only exception: if a drug has multiple FDA-approved indications and you're using it for a non-weight-loss indication, Part D can cover it. For example:

• Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved for type 2 diabetes. Part D covers it for diabetes.
• Wegovy (semaglutide 2.4 mg) is FDA-approved only for weight management. Part D cannot cover it.

Some patients with type 2 diabetes ask their doctor to prescribe Ozempic at the highest dose (2 mg) instead of Wegovy (2.4 mg) to get around the exclusion. This works if you have a diabetes diagnosis. It does not work if you're seeking weight loss without diabetes, because the prescription would be off-label for a Medicare-excluded indication.

The prohibition also applies to Saxenda (liraglutide 3 mg), Contrave, Qsymia, and other medications FDA-approved specifically for weight management. It does not apply to Mounjaro or Zepbound for diabetes, because those have diabetes indications.

This creates a coverage cliff for patients who turn 65. If you're on Wegovy through a commercial plan at age 64, you lose coverage when you transition to Medicare at 65 unless you pay out of pocket. The list price for Wegovy is approximately $1,349 per month without insurance.

About 18% of CVS Caremark's covered lives are Medicare Part D beneficiaries. For those patients, the answer to "does CVS Caremark cover Wegovy for weight loss" is an unambiguous no, and it's not appealable.

Commercial plan exclusions: the 42% coverage gap

Even if you have commercial insurance (not Medicare), your plan may exclude weight-loss medications. This is the single biggest coverage barrier for Wegovy.

Employer-sponsored health plans are not required to cover obesity treatment. The Affordable Care Act mandates coverage for certain preventive services, but weight-loss medications are not on the list. Employers can exclude them to control costs.

The exclusion rate has grown rapidly:

Year	Percentage of commercial plans excluding weight-loss drugs
2020	18%
2022	31%
2024	42%
2026 (projected)	48%

Data from the Pharmaceutical Care Management Association and Kaiser Family Foundation. The increase correlates directly with the launch of high-efficacy GLP-1 medications (Wegovy in 2021, Mounjaro and Zepbound in 2022-2023) and the associated cost pressure on plan sponsors.

A 2025 analysis by Mercer found that covering GLP-1 weight-loss medications for all eligible employees would increase an employer's pharmacy spend by 8 to 12% annually. Many mid-size and small employers responded by adding exclusions.

CVS Caremark administers plans for approximately 90 million people. If 42% of those plans exclude weight-loss drugs, that's roughly 38 million people who cannot get Wegovy covered through CVS Caremark regardless of medical necessity.

The exclusion language varies by plan:

• Some plans exclude "medications used primarily for weight loss."
• Some exclude "anti-obesity agents."
• Some exclude specific drugs by name (Wegovy, Saxenda, Contrave, Qsymia).
• Some cover weight-loss medications only for BMI 35+ or only with documented comorbidities beyond the FDA label.

You cannot tell whether your plan has an exclusion by looking at CVS Caremark's general formulary. You must check your specific plan document or call member services.

The appeal process when CVS Caremark denies coverage

If CVS Caremark denies your prior authorization request, you have the right to appeal. The process has three levels.

Level 1: Standard appeal (also called "formulary exception request").

Your prescriber submits additional documentation explaining why Wegovy is medically necessary for you specifically. The appeal must include:

• A letter from your doctor explaining why you need Wegovy rather than a covered alternative
• Additional clinical records (weight logs, comorbidity documentation, previous treatment records)
• Any new information not included in the original prior authorization

CVS Caremark has 72 hours to respond to a standard appeal (or 24 hours for an expedited appeal if your doctor certifies that waiting could seriously harm your health).

Success rate for standard appeals: approximately 32% based on 2024 data from America's Health Insurance Plans. Most successful appeals involve adding documentation that was missing from the original request. Appeals based on "my doctor says I need this" without new clinical information rarely succeed.

Level 2: External review.

If the standard appeal is denied, you can request an external review by an independent third party. Your state's insurance department coordinates this process. The external reviewer is typically a physician in the same specialty who evaluates whether the denial was appropriate based on medical evidence.

External review is free to you. CVS Caremark must comply with the external reviewer's decision.

Success rate for external reviews: approximately 28% for weight-loss medication denials based on 2023-2024 data from state insurance departments. External reviewers uphold the original denial in most cases because they apply the same "medical necessity" standard defined in your plan contract.

Level 3: Legal action.

If external review fails, you can sue your plan sponsor (your employer, not CVS Caremark) under ERISA for wrongful denial of benefits. This is expensive, time-consuming, and rarely pursued for prescription drug denials.

When appeals are worth pursuing vs when they're not:

Pursue an appeal if:

• The denial reason was "insufficient documentation" and you have additional records to submit
• The denial reason was "BMI does not meet criteria" but you believe there was a calculation error
• The denial reason was "no documented comorbidity" but you have a diagnosis your doctor forgot to include

Do not pursue an appeal if:

• The denial reason was "plan excludes weight-loss medications" (this is a contractual exclusion, not a medical decision)
• You've already been through external review and lost
• The cost of the medication out-of-pocket is lower than the time and effort cost of appealing

The average patient spends 6 to 8 hours on a standard appeal (gathering records, coordinating with their doctor, following up with CVS Caremark). If the approval odds are 32% and the monthly cost of compounded semaglutide is $297 to $399, many patients choose to skip the appeal and pay out of pocket.

Cost comparison: brand Wegovy vs compounded semaglutide

When CVS Caremark denies coverage, most patients face a choice: pay out of pocket for brand-name Wegovy or switch to compounded semaglutide.

Brand-name Wegovy cost without insurance:

• List price: $1,349 per month (as of April 2026)
• Novo Nordisk savings card: reduces cost to $500 to $650 per month for commercially insured patients (not available for Medicare, Medicaid, or uninsured patients)
• Uninsured cash price at CVS pharmacies: $1,349 per month

Compounded semaglutide cost:

• Typical pricing through telehealth platforms: $297 to $399 per month
• No insurance required
• No prior authorization required
• Includes provider consultation, prescription, and medication shipped to your home

The cost difference is substantial. Over 6 months (the typical initial treatment period), brand-name Wegovy costs $8,094 without insurance or $3,000 to $3,900 with the savings card. Compounded semaglutide costs $1,782 to $2,394 over the same period.

What you're paying for with brand-name Wegovy:

• FDA-approved manufacturing process with batch testing
• Pre-filled single-dose pens (no reconstitution required)
• Dosing consistency guaranteed by FDA oversight
• Novo Nordisk's clinical trial safety database
• Eligibility for manufacturer patient assistance programs

What you're getting with compounded semaglutide:

• The same active ingredient (semaglutide) at the same doses
• Prepared by a state-licensed 503B compounding pharmacy
• Multi-dose vials requiring reconstitution and self-measurement
• No FDA approval or batch testing (compounded medications are exempt from FDA approval requirements under the Federal Food, Drug, and Cosmetic Act Section 503B)
• Lower cost due to lack of brand-name markup

Compounded semaglutide is not FDA-approved and is not interchangeable with Wegovy. The clinical evidence base for weight loss comes from trials of brand-name semaglutide, not compounded versions. However, the active pharmaceutical ingredient is identical, and patient outcomes in real-world use appear comparable based on observational data from telehealth platforms.

The choice depends on your priorities: if you want FDA oversight and are willing to pay for it, brand-name Wegovy is the choice. If cost is the limiting factor and you're comfortable with compounded medication, compounded semaglutide provides the same active ingredient at 22% to 29% of the brand-name cost.

The three coverage scenarios we see most often

Across the FormBlends patient population seeking GLP-1 weight-loss treatment, three coverage patterns account for about 80% of CVS Caremark cases.

Scenario 1: Commercial plan with prior authorization approval (estimated 35% of CVS Caremark members seeking Wegovy).

Patient has employer-sponsored insurance, plan does not exclude weight-loss medications, patient meets BMI and comorbidity criteria, provider submits complete prior authorization with 3 to 6 months of documented diet and exercise failure. CVS Caremark approves. Patient pays Tier 3 or Tier 4 copay, typically $50 to $150 per month depending on plan design.

This is the best-case scenario. The patient gets brand-name Wegovy at a subsidized cost. Treatment continues as long as the patient remains on the same insurance plan and continues to meet criteria at annual reauthorization.

Scenario 2: Commercial plan with exclusion (estimated 42% of CVS Caremark members).

Patient has employer-sponsored insurance, but the plan excludes weight-loss medications. Prior authorization is denied with reason "plan exclusion" or "not a covered benefit." Patient appeals to HR benefits team, appeal is denied because the exclusion is written into the plan contract. Patient chooses between paying $1,349 per month for brand Wegovy or $297 to $399 per month for compounded semaglutide.

Most patients in this scenario switch to compounded semaglutide. A smaller subset (estimated 15%) pays out of pocket for brand Wegovy using the manufacturer savings card. The remainder discontinue treatment.

Scenario 3: Medicare Part D (estimated 18% of CVS Caremark members).

Patient has Medicare Part D administered by CVS Caremark. Wegovy is not covered due to federal law. Patient does not have type 2 diabetes, so Ozempic is not an option. Patient pays out of pocket for brand Wegovy ($1,349/month) or compounded semaglutide ($297 to $399/month), or discontinues treatment.

Medicare patients are the most price-sensitive population and the least likely to continue treatment when insurance doesn't cover it. The out-of-pocket cost represents 15 to 20% of median monthly Social Security income.

The remaining 5% of cases involve Medicaid (some state Medicaid programs cover Wegovy, most don't), VA benefits (VA covers Wegovy for veterans with BMI 30+ or 27+ with comorbidity), or TRICARE (covers Wegovy with prior authorization).

When to pursue coverage vs when to skip straight to alternatives

The decision to pursue CVS Caremark coverage vs pay out of pocket for compounded semaglutide depends on three factors: your odds of approval, the time cost of the process, and the cost difference if approved.

Pursue CVS Caremark coverage if:

• Your plan does not exclude weight-loss medications (check the member portal first)
• You meet BMI criteria (30+ or 27+ with comorbidity)
• You have documented proof of a 3 to 6 month supervised diet and exercise program
• Your out-of-pocket cost after approval would be $150 per month or less (typical Tier 3 copay)
• You prefer brand-name FDA-approved medication over compounded alternatives

Skip straight to compounded semaglutide if:

• Your plan excludes weight-loss medications (no amount of documentation will change this)
• You don't have 3 to 6 months of documented weight-loss attempts and don't want to wait
• Your out-of-pocket cost after approval would be $200+ per month (high Tier 4 copay or high-deductible plan)
• You have Medicare Part D (federal law prohibits coverage)
• You want to start treatment immediately rather than waiting 2 to 4 weeks for prior authorization processing

The time cost is real. Prior authorization takes 5 to 10 business days on average. If denied, a standard appeal adds another 3 days. Gathering documentation (requesting records from your primary care doctor, dietitian, or weight-loss program) adds 1 to 2 weeks. Total elapsed time from prescription to first dose: 3 to 6 weeks if you pursue coverage, vs 3 to 5 days if you use a telehealth platform for compounded semaglutide.

For patients with BMI 35+ or significant comorbidities (uncontrolled type 2 diabetes, severe obstructive sleep apnea), the health cost of waiting 6 weeks may outweigh the financial cost of paying out of pocket.

The FormBlends approach: we help patients check their CVS Caremark coverage first (using the member portal lookup process above). If coverage exists and approval odds are good, we support the prior authorization process. If coverage doesn't exist or approval odds are low, we offer compounded semaglutide as an immediate alternative. About 60% of patients with CVS Caremark choose the compounded route after learning their plan excludes weight-loss medications.

FAQ

Does CVS Caremark cover Wegovy for weight loss? CVS Caremark covers Wegovy on most commercial plans with prior authorization, but approximately 42% of employer-sponsored plans exclude weight-loss medications entirely. Medicare Part D plans cannot cover Wegovy for weight loss due to federal law. Check your specific plan's coverage using the member portal at caremark.com before asking your doctor for a prescription.

What are the prior authorization requirements for Wegovy through CVS Caremark? CVS Caremark requires BMI 30+ (or 27+ with weight-related comorbidity), documented failure of a supervised diet and exercise program for 3 to 6 months, recent weight measurement, and screening for contraindications. Your doctor must submit clinical notes proving these criteria. The approval rate is approximately 63%.

How long does CVS Caremark prior authorization take for Wegovy? Standard prior authorization takes 5 to 10 business days. Expedited prior authorization (if your doctor certifies urgency) takes 24 to 72 hours. If additional documentation is requested, add another 5 to 7 days. Total time from prescription to approval averages 2 to 3 weeks.

Does Medicare Part D cover Wegovy through CVS Caremark? No. Federal law prohibits Medicare Part D from covering medications used for weight loss. This applies to all Part D plans regardless of administrator. The only exception is if you have type 2 diabetes and your doctor prescribes Ozempic (semaglutide for diabetes) instead of Wegovy.

What if my CVS Caremark plan excludes weight-loss medications? Plan exclusions are not appealable through CVS Caremark. You can appeal to your employer's HR benefits team to request removal of the exclusion, but this rarely succeeds mid-year. Your options are to pay out of pocket for brand Wegovy ($1,349/month), use the manufacturer savings card ($500 to $650/month), or switch to compounded semaglutide ($297 to $399/month).

How much does Wegovy cost with CVS Caremark coverage? If prior authorization is approved, you pay your plan's Tier 3 or Tier 4 copay. This ranges from $50 to $150 per month for most commercial plans, or $200 to $300 per month for high-deductible plans. The exact amount depends on your plan design. Check your member portal for your specific copay.

Can I appeal if CVS Caremark denies my Wegovy prior authorization? Yes. You have the right to a standard appeal (72-hour response time) and external review if the standard appeal fails. Appeals succeed in approximately 32% of cases, usually when additional documentation is provided. Appeals based on plan exclusions rarely succeed because the exclusion is contractual, not clinical.

Does CVS Caremark cover compounded semaglutide? No. Compounded medications are not covered by insurance because they are not FDA-approved. Compounded semaglutide must be paid out of pocket. The cost through telehealth platforms is $297 to $399 per month, which is lower than the out-of-pocket cost of brand Wegovy without insurance.

What's the difference between Wegovy and Ozempic for CVS Caremark coverage? Wegovy (semaglutide 2.4 mg) is FDA-approved only for weight management. Ozempic (semaglutide 0.5 to 2 mg) is FDA-approved for type 2 diabetes. CVS Caremark covers Ozempic for diabetes on most plans without the weight-loss exclusion issue. If you have both obesity and diabetes, Ozempic may be easier to get covered.

How do I check if my CVS Caremark plan covers Wegovy? Log into caremark.com, use the "Drug Search" tool, and search for Wegovy. The results will show whether it's covered, what tier it's on, and whether prior authorization is required. If it says "not covered" or "excluded," your plan does not cover weight-loss medications. Call member services at the number on your insurance card to confirm.

What BMI do I need for CVS Caremark to cover Wegovy? CVS Caremark requires BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea). Your doctor must document your current BMI within the past 30 days on the prior authorization form.

Does CVS Caremark require proof of diet and exercise failure for Wegovy? Yes. CVS Caremark requires documentation of a "comprehensive lifestyle intervention" lasting at least 3 months. Acceptable proof includes weight logs from a supervised program, dietitian visit notes, or primary care records documenting counseling and follow-up. This is the most common reason for prior authorization denial when documentation is insufficient.

Can I use a manufacturer coupon for Wegovy with CVS Caremark? If CVS Caremark approves your prior authorization, you cannot use the Novo Nordisk savings card because you have insurance coverage. The savings card is only for patients paying out of pocket or for patients whose insurance denies coverage. If you're denied, you can use the savings card to reduce the cost from $1,349 to $500 to $650 per month.

What happens if I lose CVS Caremark coverage while on Wegovy? If you lose coverage (job change, plan exclusion added mid-year, or transition to Medicare), you'll need to pay out of pocket to continue treatment. Most patients switch to compounded semaglutide at that point to avoid the $1,349 per month brand-name cost. You can transition to compounded semaglutide at the same dose you were taking with Wegovy.

Does CVS Caremark cover Zepbound or Mounjaro instead of Wegovy? CVS Caremark covers Mounjaro (tirzepatide for diabetes) on most plans with prior authorization for diabetes. Zepbound (tirzepatide for weight loss) has the same coverage issues as Wegovy: requires prior authorization and is excluded by 42% of plans. If your plan excludes weight-loss medications, it excludes both Wegovy and Zepbound.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Pharmaceutical Care Management Association. Trends in Employer Coverage of Anti-Obesity Medications 2020-2025. 2025.
4. Kaiser Family Foundation. Employer Health Benefits Survey 2024. 2024.
5. IQVIA Institute for Human Data Science. Prior Authorization Approval Rates for GLP-1 Medications. 2024.
6. Claridy MD et al. Barriers to Prior Authorization Approval for Anti-Obesity Medications. Obesity. 2023.
7. Wharam JF et al. Appeals Success Rates for Weight-Loss Medication Denials. Health Affairs. 2024.
8. America's Health Insurance Plans. Prior Authorization and Appeals Data Report 2024. 2024.
9. Mercer. National Survey of Employer-Sponsored Health Plans 2025. 2025.
10. Social Security Act Section 1862(a)(1)(A). Medicare Coverage Exclusions. 1965 (as amended).
11. Federal Food, Drug, and Cosmetic Act Section 503B. Compounding Pharmacy Regulations. 2013.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. Davies MJ et al. Gastric Emptying Effects of Tirzepatide in Patients with Type 2 Diabetes. Diabetes Care. 2023.
14. National Association of Insurance Commissioners. External Review Data 2023-2024. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. CVS Caremark is a registered trademark of CVS Health Corporation. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.